Pioneering the development
of engineered IgM antibodies

antibody-solo

IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

– Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in…

Read More...

IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020

MOUNTAIN VIEW, Calif., March 19, 2020 – IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology…

Read More...

IGM Biosciences to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., March 04, 2020  — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company…

Read More...

IGM Biosciences to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Feb. 06, 2020 – IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in…

Read More...

IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis

Expert in the research and development of apoptotic pathways and antibody drug conjugates. MOUNTAIN VIEW,…

Read More...

IGM-2323: High Avidity IgM-based CD20xCD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

Read More...